RET inhibitors for patients with RET fusion-positive and RET wild-type non-small-cell lung cancer
Mené sur 26 patients atteints d'un cancer du poumon non à petites cellules, de stade métastatique ou non résécable, présentant des réarrangements du gène RET, cet essai de phase II évalue l'efficacité, du point de vue du taux de réponse globale, du cabozantinib
Cabozantinib and vandetanib, multikinase inhibitors with several targets including RET, are US Food and Drug Administration approved for the treatment of metastatic medullary thyroid carcinoma harbouring RET mutations or chromosomal rearrangements (gene fusions) of the RET receptor tyrosine kinase. RET fusion-positive tumours have been reported in non-small-cell lung cancer (NSCLC), papillary thyroid carcinoma, and myelomonocytic leukaemia. Several RET fusions have been identified in NSCLC, including KIF5B-RET, CCDC6-RET, NCOA4-RET, and TRIM33-RET.
The Lancet Oncology , commentaire, 2015